Latest Breaking News On - லிசா ரேஹ்ம் - Page 1 : comparemela.com

(0) - Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose - NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the company s lead therapeutic candidate. The open-label, multicenter study will evaluate CBX-12 in patients with advanced or metastatic refractory solid tumors. The primary objectives of Phase 1 are to determine the safety and tolerability, maximum tolerated doses and dose limiting toxicities of CBX-12, and to establish the recommended Phase 2 dose of CBX-12. Two Phase 2 expansion cohorts will evaluate patients with platinum-resistant ovarian cancer and small cell lung cancer.

Kostenloser wertpapierhandelMark corbaeStephanie carringtonLisa rehmYale universityHlip incUniversity of rhode islandTechnology platformPeptide drug conjugatePer hellsundH low insertion peptidesRhode islandமாற்றாந்தாய் கேரிங்டன்லிசா ரேஹ்ம்யேல் பல்கலைக்கழகம்பல்கலைக்கழகம் ஆஃப் ரோட் தீவு